

| OMB APPROVAL             |           |
|--------------------------|-----------|
| OMB Number:              | 3235-0287 |
| Estimated average burden |           |
| hours per response:      | 0.5       |

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|  |   |  |
|--|---|--|
| 1. Name and Address of Reporting Person*<br><u>BAUM MARK L</u><br><br>(Last) (First) (Middle)<br><u>C/O IMPRIMIS PHARMACEUTICALS, INC</u><br><u>12264 EL CAMINO REAL, SUITE 350</u><br><br>(Street)<br><u>SAN DIEGO CA 92130</u><br><br>(City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol<br><u>Imprimis Pharmaceuticals, Inc. [ IMMY ]</u> | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br><br><input checked="" type="checkbox"/> Director 10% Owner<br><input checked="" type="checkbox"/> Officer (give title below) Other (specify below)<br><u>Chief Executive Officer</u> |
|  | 3. Date of Earliest Transaction (Month/Day/Year)<br><u>12/19/2016</u>                         |  |
| 4. If Amendment, Date of Original Filed (Month/Day/Year)   |   |  |

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |        | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|--------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price  |   |  |   |
| Common Stock                    | 12/19/2016                           |  | p <sup>(1)</sup>               |   | 156,000   | A          | \$1.79 | 325,835   | D  |   |
| Common Stock <sup>(2)</sup>     | 12/19/2016                           |  | M                              |   | 200,000   | A          | \$1.72 | 525,835   | D  |   |
| Common Stock <sup>(2)</sup>     | 12/19/2016                           |  | D                              |   | 83,709  | D          | \$1.72 | 442,126   | D  |   |

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |     | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |                            | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----|--|-----------------|---|----------------------------|--|--|---|--|
|  |  |                                      |  | Code                           | V | (A)  | (D) | Date Exercisable   | Expiration Date | Title   | Amount or Number of Shares |  |  |   |  |
| Purchase Warrant                           | \$1.79   | 12/19/2016                           |  | p <sup>(1)</sup>               |   | 156,000  |     | 06/23/2016   | 12/23/2019      | Common Stock  | 156,000                    | \$0.125 <sup>(3)</sup>                     | 156,000  | D   |  |
| Restricted Stock Unit <sup>(2)</sup>       | \$0  | 12/19/2016                           |  | M                              |   | 200,000  |     | (2)  | (2)             | Common Stock  | 200,000                    | \$0  | 0  | D   |  |

**Explanation of Responses:**

- On December 19, 2016, the Beadore Trust dated March 20, 2015, through which Mr. Baum has voting and investment control over the securities, entered into a definitive agreement to acquire 156,000 Units of Imprimis Pharmaceuticals, Inc.'s (the "Company"), with each Unit consisting of one share of common stock, and a warrant to purchase one share of the Company's common stock, as part of a private placement by the Company to accredited investors.
- On December 19, 2016, restricted stock units granted to Mr. Baum on May 2, 2013, and previously vested, were issued and then transferred into the Beadore Trust dated March 20, 2015. 83,709 shares of common stock were withheld from issuance to Mr. Baum for payroll tax purposes.
- The value of the Purchase Warrant included in each Unit is \$0.125.

/s/ Mark L. Baum

12/21/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.